{'fraction_non_alphanumeric': 0.013447432762836185, 'fraction_numerical': 0.019559902200488997, 'mean_word_length': 5.251908396946565, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Recent progress in 5-HT6 receptor antagonists for the treatment of CNS diseases

In light of the barrage of recent reviews on 5-HT6 receptor antagonists, this article highlights and reviews the research advances published in patent literature between January 1998 and December 2001. The article is supplemented with selected references on design, synthesis and development of novel 5-HT6 agents to treat CNS diseases and to study and understand their mechanism and pathophysiology. Emphasis is given to recent advances in the possible involvement of 5-HT6 serotonergic agents in the treatment of schizophrenia and depression. By no means has any attempt been made to exhaustively review the literature but rather, primary references along with citations to recent literature reviews have been included in each section.